| Yamauchi,201511) | Meta-analysis | 987 | 0.86 | 0.94 | High sensitivity and NPV in early HNSCC |
| Liu,20175) | Meta-analysis | 3,566 | 0.87 | 0.94 | High sensitivity and NPV in OSCC |
| Yang,20176) | Meta-analysis | 1,084 | 0.92 | 0.96 | High sensitivity and NPV in early tongue SCC |
| Molstrom,201913) | Prospective cohort | 220 | 0.83 | 0.93 | Identified atypical lymphatic drainage |
| den Toom,201914) | Retrospective multicenter cohort | 53 | 0.75 | 0.98 | SLNB feasible after previous neck treatment |
| Kim,20217) | Systematic review/meta-analysis | 5,917 | 0.83 | NR | High specificity supports SLNB as staging tool |
| Garrel,202012) | Phase III randomized equivalence trial | 279 analyzed | NR | NR | Oncologic equivalence to END with lower morbidity |
| Hasegawa,202115) | Randomized multicenter noninferiority trial | 271 | NR | NR | Noninferior to END with reduced neck disability |
| Mallo Magarinos,20218) | Systematic review/meta-analysis | 457 | 0.88 | 0.88 | High sensitivity and specificity in T1/T2-N0 OSCC |
| Ionna,20249) | Retrospective cohort | 122 | NR | NR | High detection rate supports SLNB staging |
| Kolev,202610) | Consecutive cohort | 40 | 0.92 | 0.96 | High sensitivity and NPV in OTSCC |
| Seferin,202516) | Prospective non-randomized comparative study | 70 | 0.78 | 1.00 | No significant survival difference vs SND |